Penwest Pharmaceuticals — Proxy Contest (May 2009)
32 slides from Penwest Pharmaceuticals's proxy contest presentation, May 22, 2009
Slide 1: Focused Strategy to Drive Shareholder Value
Focused Strategy to Drive Shareholder Value Jennifer Good President , CEO & Director May 21, 2009
Slide 2: Forward-looking Statements
Forward-looking Statements The matters discussed herein contain forward-looking statements that involve risks and uncertainties, which may cause the actual results in future periods to be materially different from any future performance suggested herein. For this purpose, any statements contained he
Slide 3: Information Concerning Participants
Information Concerning Participants Information required to be disclosed with regard to the Company's directors, director nominees, officers and employees who, under the rules of the Securities and Exchange Commission (the "SEC"), are considered to be "participants" in the Company's solicitation of
Slide 4: Who We Are & What We Do
WHO WE ARE & WHAT WE DO 1 Ponwest
Slide 5: Our Business
Our Business Drug development company focused on identifying and developing products that address unmet medical needs, primarily for rare disorders of the nervous system A0001 is lead development asset. Also have rights to an additional NCE from Edison Also license our drug delivery technologies and
Slide 6: 2009 Strategy
2009 Strategy Focused strategy to drive shareholder value. The Company's plan for 2009 consists of the following key components: Maximize Opana revenues in partnership with Endo Advance A0001 to establish proof of concept for safety and biological activity Monetize the value of the Company's proven
Slide 7: 2009 Value Drivers
2009 Value Drivers We believe that by pursuing this strategy, we can enter 2010: As a profitable and cash flow positive Company Opana ER contributing at the full royalty rate Additional assets out licensed to create incremental long term growth On a path towards demonstrating proof of concept around
Slide 8: Opana ER
Opana(r) ER Developed using Penwest's TIMERx technology Marketed by Endo Pharmaceuticals Indication: For the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time Endo's Opana ER Sales 1st Quarter Sales YTD Sales 2009 $ 4
Slide 9: Opana ER TRx Demand
Opana ER TRx Demand Source: IMS Monthly TRx data Quarterly demand exceeding 130,000 Rxs Quarterly Rx demand grew by over 50% in past year Strong Growth Trend in Quarterly TRx Volume
Slide 10: Opana ER Financials - U.S.
Penwest receives a tiered royalty based upon annual U.S. net sales of Opana ER 22% up to $150m in annual net sales 25%+ increasing in regular increments with net sales Top rate of 30% on sales Recorded $4.4m of royalty revenue for Q1 '09 Agreed to repay $28M in unfunded development costs through a t
Slide 11: Opana ER ex-U.S.
Worldwide rights ex-U.S. are jointly owned with Endo Economics to be shared 50/50 Penwest took the business development lead for Opana outside the U.S. in November 2008 Currently seeking licensees in several ex-U.S. territories; we believe a deal can be signed by the end of the first half of this ye
Slide 12: Patents - Opana ER
Patents - Opana ER Multiple generic filers in the U.S. Penwest and Endo have sued all generic filers First 30-month stay ends June 2010 Latest patent expires in 2013 Multiple additional clinical and formulation patent applications being prosecuted by Penwest and Endo. Beginning in late 2007, this cr
Slide 13: A0001 Orphan Neurological Diseases
Development of orphan drugs has risks, but is approachable for a small company: Receptive regulatory environment worldwide Reasonably sized clinical trials Marketing through specialty niche model Market exclusivity protection of 7 years in U.S. and 10 years in Europe A0001 Orphan Neurological Diseas
Slide 14: Rare Disorder Strategy Can Drive Shareholder Value
Rare Disorder Strategy Can Drive Shareholder Value
Slide 15: A0001 - Why We Think It Is Exciting
A0001-Why We Think It Is Exciting... Compound is alpha-tocopherol quinone Co-enzyme Q class of drug. High dose co-enzyme Q supplementation is proven to have some effect in mitochondrial diseases. A0001 is significantly more bioavailable than co-enzyme Q Marketed in the 70's in France as a compound f
Slide 16: A0001 - Clinical Program
A0001 - Clinical Program Diverse set of clinical syndromes that result from defects or damage to a specific group of mitochondria that are necessary for cellular respiration. Two common biochemical pathologies: Inability to generate chemical energy (ATP) Increased free radical oxygen production Clin
Slide 17: "Myths" about A0001
"Myths" about A0001 "A0001 is nothing more than a metabolite of vitamin E that has no patent protection, is many years behind a competitor targeting the same, limited market, and is targeting an indication for which there are no validated surrogate markers of efficacy, necessitating a very long, exp
Slide 18: "Myths" about A0001: no patent protection
"Myths" about A0001 "... that has no patent protection" Orphan Drug Exclusivity A0001 received orphan drug designation in the U.S., which makes A0001 eligible for 7 years of post-approval market exclusivity Also applying in Europe for orphan drug designation which would make A0001 eligible for 10 ye
Slide 19: "Myths" about A0001: no validated surrogate markers
"Myths" about A0001 "... targeting an indication for which there are no validated surrogate markers of efficacy, necessitating a very long, expensive and uncertain development path." We believe it is important to turn over the card on safety and biological activity Q1 2010. If the drug clears these
Slide 20: 2009 A0001 Development Plan
2009 A0001 Development Plan Commenced MAD dosing in Q2; data by end of June Commenced 6 month preclinical tox program; expect data by year end to enable longer clinical program in patients Initiate Phase IIa trial in H2 '09 with data expected in Q1 '10 The goal of these trials is to establish proof
Slide 21: TIMERx Technology
TIMER«x Technology
Slide 22: Drug Delivery Technology Licensing
Pursuing technology licensing collaboration with companies utilizing our extended release technologies and formulation expertise Provides stability during the development of our own portfolio Leverages Company asset and capability Covers the fully loaded salaries of approximately 8 people and a port
Slide 23: Goals for Drug Delivery - 2009
Goals for Drug Delivery - 2009 Sign at least 2 additional deals. We expect that this business at least breaks even on a fully loaded basis with 2 deals a year Advance the 3 compounds currently under development to deliver the targeted formulations to collaborator Maintain upside on drugs from the ro
Slide 24: Financially Solid - 2009 Guidance
Financially Solid - 2009 Guidance 2009 Guidance 2008 Actual % Change Revenues $ 22 - 24m $ 8.5m 171% S,G &A 9 - 10m 12.1m (21)% R&D 12 - 14m 21.0m (38)% Net Loss $(1) - (3)m $( 26.7)m (93)% Q1 '09 opex was down 45% from Q1 '08 Improvement being driven by increased revenues and decreased operating ex
Slide 25: Details of Cost Cutting Effort
Details of Cost Cutting Effort Reduced headcount from 76 to 48 employees or 37% through 2 RIF's (Q1 '08 & Q1 '09) Reduced 2008 & 2009 salary increases, and executive officers took no increase in 2009 Narrowed the R&D portfolio to ensure adequate funding (nalbuphine on hold) Drug delivery collaborati
Slide 26: Balance Sheet
Balance Sheet Cash March 31, 2009 $ 15.0m Line of Credit at March 31, 2009 Repaid monthly through Sept 2010 $ 8.2m No capital required to execute business plan Current cash expected to bridge us to profitability No capital required to execute business plan Current cash expected to bridge us to profi
Slide 27: Penwest 2009 Key Milestones
Opana ER Increasing sales by our partner Endo Additional issued patents Ex-U.S. marketing collaborations with at least one signed by end H1 '09 A0001 Complete Phase Ib multiple ascending dose safety study in healthy volunteers with data by end of Q2 '09 Conduct six month preclinical tox program Init
Slide 28: Opposing Strategy: Vote for Shareholder Value or Vote to Call It Quits
Opposing Strategy Vote for Shareholder Value or Vote to Call It Quits Tang/Edelman Strategy: "...immediately winding down substantially all of the Company's operations..." Board unanimously disagrees for the following reasons: Leaves assets on the table which have not realized their full value (Opan
Slide 29: Opposing Strategy: Risk of losing NOL tax carryforwards
Opposing Strategy Risk of losing access to the majority of our $91 million of available net operating loss tax carryforwards In 2008, Perceptive triggered a change in control under tax rules, which cost us access to $123 million of NOL's and an additional loss of $7 million in tax credits Under Sec
Slide 30: Opposing Strategy: Risk of losing NASDAQ listing
Opposing Strategy Risk of losing our NASDAQ listing because Penwest would be a "public shell" A public shell is defined as "A company with no or nominal operations and either no or nominal assets, assets consisting solely of cash and cash equivalents..." Company would likely be delisted, impairing s
Slide 31: Conclusion
Conclusion Board unanimously believes that our strategy can build shareholder value in the short-term and prepare the Company for long-term growth by: Maximizing Opana revenues in partnership with Endo Advancing A0001 to establish proof of concept for safety and biological activity Monetizing the va
Slide 32: AaFenwest
AaFenwest (Nasdaq: PPCO) May 21, 2009 ~aPenwest